TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05251571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Coordination Group with Telerehabilitation
Description: Functional muscle strengthening, stretching, balance and coordination exercises given with telerehabilitation are applied.
Study: NCT06180733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.
Study: NCT06066983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DINOSAUR
Description: This intervention aims to treat intolerance of uncertainty and anxiety in young autistic children.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: This intervention provides psychoeducation regarding anxiety and autism.
Study: NCT04823741

Intervention type: GENETIC
Intervention: PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA
Description: All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).
Study: NCT05549414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios
Study: NCT06322017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhythm control by Pulmonary Vein Isolation (PVI) procedure
Description: The PVI procedure involves the creation of a circumferential lesion around the ostium of the four pulmonary veins.~The choice of the type of energy to insure the lesion will be left to the discretion of the investigator, according to the center's habits and the patient's anatomy found on the scanner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)
Description: Ventricular rate control is carried out using negative chronotropic agents (e.g. beta-blockers, calcium channel blockers, digitalis, etc.) according to current recommendations. If this fails, ablation of the atrioventricular junction with placement of a permanent pacemaker can be carried out according to current recommendations. As part of this research, the choice of bradycardic drugs and interventions will be left to the discretion of the investigator according to the center's practices and current recommendations.~Rhythm control aims to reduce AF by cardioversion (if it persists) to restore sinus rhythm and subsequently maintain it by introducing anti-arrhythmic treatment. Several antiarrhythmic drugs (flecainide, sotalol or amiodarone) can be used in this setting. As part of this research, the choice of antiarrhythmic drugs will be left to the discretion of the investigator according to the center's practices and current recommendations.
Study: NCT04573192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19TNF
Description: Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
Study: NCT06318182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Young men who are included in the research sample and agree to participate in the study will be given training within the scope of the health belief model.
Study: NCT05139238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Intravenous labetalol, a short acting ant-hypertensive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Oral nifedipine, a short acting ant-hypertensive
Study: NCT05608798

Intervention type: DEVICE
Group type: OTHER
Intervention: ODI-Tech medical device
Description: The device captures and stores frames of the movement of blood in capillaries and spectra containing information on oxygen saturation. Proprietary software is used to analyse the obtained frames and spectra to calculate microvascular parameters such as functional capillary density and microvascular oxygen saturation.~ODI-Tech can be brought to the patient's bedside and operates non-invasively. The device parts are in contact with the patient for less than 5 minutes.
Study: NCT04573192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
Study: NCT05009914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac denervation
Description: Excision of Marshall ligament and Waterstone fat pad during CABG.
Study: NCT04769063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Gluteus medius facilitation and knee spiral taping techniques will be applied to treat dynamic knee valgus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Gluteus medius facilitation and knee spiral taping techniques will be applied to treat dynamic knee valgus
Study: NCT05259995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Medicine
Description: The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
Study: NCT04737161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T regulatory cells
Description: T regulatory cells isolated by immunomagnetic selection; donor cells collected through large volume apheresis.
Study: NCT04826575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity inspiratory and expiratory muscle training
Description: Inspiratory Muscle Training will be performed using the Threshold inspiratory muscle trainer device (Threshold IMT®, Philips Respironics, Inc., Murrysville, PA, USA).~Expiratory muscle training (EMT) will be performed using the Threshold positive expiratory pressure device (Threshold PEP®, Philips Respironics, Inc., Murrysville, PA, USA) or Expiratory Muscle Strength Trainer EMST 150TM (Aspire Products), depending on the initial MEP.~Patients will train 2 times a day, 7 days per week, for 2 weeks.
Study: NCT05180279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-day sleep lab
Description: Patients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored. They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection. Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.
Study: NCT05090098

Intervention type: OTHER
Intervention: None intervention
Description: None intervention

Intervention type: OTHER
Intervention: None intervention
Description: None intervention

Intervention type: OTHER
Intervention: None intervention
Description: None intervention
Study: NCT05259995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Acoustic Medicine
Description: The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
Study: NCT06169189

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: global warming-climate change based education
Description: The experimental group will be given 8 weeks of global warming-climate change based training. No intervention will be applied to the control group.
Study: NCT05345743

Intervention type: PROCEDURE
Intervention: Surgery
Description: All types of surgery requiring general anesthesia

Intervention type: PROCEDURE
Intervention: Surgery
Description: All types of surgery requiring general anesthesia
Study: NCT04953572

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: autologous peripheral blood mesenchymal stem cell
Description: Transplantation of autologous peripheral blood mesenchymal stem cell

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture + collagen membrane
Description: Microfracture plus collagen membrane transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous osteochondral transplantation
Description: Autologous osteochondral transplantation
Study: NCT05342194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib mesylate capsules
Description: 8 mg orally (po) once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IV
Description: Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral placebo
Description: Oral placebo po QD continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: Oral placebo po QD continuously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin for injection
Description: 85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin for injection
Description: 85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin for injection
Description: 85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine hydrochloride
Description: 1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride
Description: 1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride
Description: 1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
Study: NCT05570500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral health education
Description: oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral health education
Description: oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.
Study: NCT05914805

Intervention type: DRUG
Group type: OTHER
Intervention: Clascoterone 5% solution
Description: Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clascoterone 5% solution
Description: Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: OTHER
Intervention: Clascoterone 5% solution
Description: Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle solution
Description: Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle solution
Description: Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle solution
Description: Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
Study: NCT05782491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene Block
Description: It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS II Block
Description: PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial Cervical Plexus Block
Description: This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
Study: NCT04805424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipo-abdominoplasty
Description: Abdominoplasty plus liposuction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominoplasty
Description: Abdominoplasty
Study: NCT05948696

Intervention type: BEHAVIORAL
Intervention: Horticultural group therapy.
Description: Estimated 10 persons with schizophrenia who attend to a 12-week horticultural group therapy will be assessed for their experience about the program.
Study: NCT04284410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLASP-PE arm
Description: Participants will complete 8-16 weekly or twice weekly individual therapy sessions (with total session number determined by clinical need, as is typical in clinical trials of PE for PTSD), 1 therapy session (session 3) with a supportive significant other (SO), consistent with the CLASP protocol, and 11 brief (30 minute) phone calls as possible, with calls occurring every week in between therapy sessions and on a less frequent basis following treatment termination up to 3 months after the final in-person therapy session. In addition, the supportive SOs will complete 11 brief (30 minute) phone calls with the therapist at the same frequency as participants. Participants will sign a release of information prior to involving the supportive significant other in treatment.
Study: NCT06364943

Intervention type: OTHER
Group type: OTHER
Intervention: with/without dry eye syndrome
Description: compare tear ferning structure between dry eye and non-dry eye patients
Study: NCT06046391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 dose 1
Description: Liquid in vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LP-003 dose 2
Description: Liquid in vial

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid in vial
Study: NCT04849143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stingless bee honey ( Kelulut honey)
Description: The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gel dressing
Description: Smith-Nephew's Intrasite gel
Study: NCT04746989

Intervention type: DRUG
Intervention: Probenecid
Description: Probenecid claim is used as the exposure group.

Intervention type: DRUG
Intervention: Allopurinol
Description: Allopurinol claim is used as the reference group.
Study: NCT04710992

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Isolated needling procedure
Description: The needle will be inserted into the common extensor tendon of the epicondyle (dominant elbow) for 90 seconds without galvanic current.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low intensity percutaneous electrolysis
Description: Once the needle is located in the common extensor tendon of the epicondyle (dominant elbow), a single impact of galvanic current will be applied with an intensity of 0.3 mA for 90 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High intensity percutaneous electrolysis
Description: The needle will be inserted in the target position during the same time as in the other groups (90 seconds). During the first stage of intervention the needle will be imbedded without galvanic current and when the end of the application time approaches (approximately 75 seconds) three impacts of galvanic current will be applied with an intensity of 3 mA and a duration of 3 seconds each.
Study: NCT06286267

Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: Patient medical imaging materials including ultrasound, mammography, CT, MRI
Study: NCT05545878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super enhanced single vision lens 01 for spectacles
Description: This is a spectacle lens designed to have a small amount of positive power towards the bottom of the lens as this is the area that is in line with the eye when downwards for near tasks such as looking at a digital device.
Study: NCT05378048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDO-guided treatment
Description: A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care
Description: the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
Study: NCT06257134

Intervention type: OTHER
Group type: OTHER
Intervention: No systematic monitoring of symptoms
Description: No systematic monitoring of symptoms will be carried out, and patients will receive the usual care. Data collection will be carried out with the assistance of a clinical research nurse up to 12 months, then under the direction of local healthcare teams at 18 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic monitoring of symptoms
Description: once a month, individual patient scores will be sent to dialysis staff. Any score of 3 (severe symptoms) or 4 (overwhelming) on a scale of 0 to 4, on the IPOS-Renal instrument, will be permanently reported to the referrer to trigger the patient's usual symptom management.~Patients will complete 3 further HRQoL questionnaires at baseline, M6, M12 and M18: EQ-5D-5L, KDQoL-36, SONG Fatigue.~A clinical research nurse will be present in half of the participating dialysis units to help patients and dialysis teams to include and follow up patients, up to 12 months. Between 12 and 18 months, data will be collected in real life, under the guidance of local healthcare teams.~In the other half of the dialysis units, data will be collected under the direction of the local healthcare teams, who will have to organize themselves to ensure data collection. These units will also be asked to conduct semi-structured interviews as part of the qualitative phase.
Study: NCT06391476

Intervention type: OTHER
Intervention: Study of the evolution of a cohort of children born between 22 and 25 weeks gestational age
Description: * Study of mortality in a cohort of children born between 22 and 25 weeks gestational age~* Study of neonatal morbidity~* Description of postnatal growth~* Description of nutrition and breastfeeding at discharge~* Study of the neurological, respiratory and growth outcome at 2 years.